. .
  • Home
  • Research
  • Researchers

IRCM Researchers

Creating new
knowledge

Exploring new avenues to develop tomorrow’s medical knowledge through an approach that integrates basic and clinical research

Our research units are led by principal investigators who collaborate in a spirit of collegiality and with the vision of bridging the gap between research and patients. They train the next generation of scientists and are independent and creative minds who work tirelessly to improve health.

 

Yvan
Guindon

Director, Bioorganic Chemistry Research Unit

Current research

Bioorganic Chemistry

Directed by Yvan Guindon, the bioorganic chemistry is interested in the synthesis of molecules that hold potential as therapeutic agents.

The objective of this research team is to develop new methodologies and reactions.  His group was one of the first to demonstrate the feasibility of using acyclic free-radical intermediate in stereoselective reactions such as hydrogen transfer and atom transfer.  The power and versatility of these were illustrated in the synthesis of complex polypropionates, such as zincophorin, a natural product with antibacterial properties.  Novel approaches to the synthesis of nucleoside from acyclic processors are under development.  In both cases new reactions were used and their mechanism studied both experimentally and theoretically.

These studies led us to conceptualize and prepare new families of nucleoside analogues. A group of these has antitumoral activities and shows promises for the treatment of pancreatic cancer.  Another group is active in vitro and in vivo as cardioprotective agent.  It shows beneficial effects in heart failure models and in decreasing the cardiotoxicity of anti-cancer agents, clinically used.

His group has developed an expertise in Glyco-chemistry. They have prepared Sialyl Lewis X analogues which interfere with pro-inflammatory cells at the site of infection.  Studies are presently realized to evaluate their potential in the treatment of severe COVID-19 illness.

Available positions Clinical studies

Team
  • Elodie HARDINE Étudiante au doctorat PhD Student Elodie.Hardine@ircm.qc.ca
  • Ilyes BENDOUROU Étudiant maîtrise Master's Student Ilyes.Bendourou@ircm.qc.ca
  • Mathieu Truong Étudiant au doctorat Phd Student Mathieu.Truong@ircm.qc.ca
  • Michel PREVOST Chercheur associé chevronné Research Associate Michel.Prevost@ircm.qc.ca
  • Solène Huck Étudiante au doctorat Phd Student solene.huck@ircm.qc.ca
  • Starr DOSTIE Chercheuse associée Research Associate Starr.Dostie@ircm.qc.ca
  • Thomas Beaugrand Étudiant au doctorat Phd Student Thomas.Beaugrand@ircm.qc.ca
Affiliations
  • Director, Bioorganic Chemistry Research Unit
  • Full IRCM Research Professor
  • Full Research Professor, Department of Chemistry, Université de Montréal
  • Adjunct Professor, Department of Biochemistry, Microbiology and Immunology, University of Ottawa
Degrees and experience
  • Doctorate in Organic Chemistry (Ph.D) Université de Montréal (1981)
  • Diploma in Administrative Sciences (DSA), HEC (1983)
  • Director, Medicinal Chemistry, Merck-Frosst Canada (1979-1987)
  • Associate  Member of the Research Coordinating Committee (RCC):  Merck Sharp, Dohme Research Laboratories (Rahway, NJ) (1986-1987)
  • Vice-President, Research and Development, BioMega/Boehringer-Ingelheim (1987-1994)
  • Member of International Research Committee: Boehringer Ingelheim GmbH, Germany (1992-1994)
  • Member of the Board of Directors and Member of the Scientific Advisory Board for NeoKimia, Sherbrooke (1998-2001) 
  • Agence d’évaluation de la recherche et de l’enseignement supérieur (AERES, France), Chair Expert Panel responsible for the evaluation of : 
    • Institut de chimie des substances naturelles (CNRS, France) (2009)
    • Institut des biomolécules Max Mousseron (Montpellier, France) (2010)
    • Département de chimie moléculaire (DCM), Université de Grenoble (2010)
  • Member of the Board Stem Cell Network of Canada (2004-2011)
  • Member of the Nominating Committee for the Division of Chemistry, Mathematics and Physics Sciences, Academy of Sciences, Royal Society of Canada (1998-2001) / 2004-2006)
  • President Royal Society of Canada :  the Academies of Arts, Humanities and Sciences of Canada (2007-2009)
  • Member of the Research Management Committee GlycoNet (National Center of Excellence) (2015-2020)
  • Member of the Pacifichem Board (Chemical Congress of Pacific Basin Societies representing the Canadian Chemistry Society (CSC) (2015-      ).
Publications

Patents

“New E- And P-Selectin Antagonists and Their Application To Modulate Hyperinflammation.”, 2024, Application # US 63/676,706, July 28, 2024. Applicants (IRCM, Université d’Ottawa), Inventors :  Guindon, Y.; Prévost, M.; Nemer, M.
 
“Nucleoside and Nucleotide Analogues Bearing a Quaternary All-carbon Stereocenter at the 2’ Position and Methods of Use as a Cardioprotective Agent”, 2017, Application # PCT/CA2017/051095; International Publication Date March 22, 2018, WO2018/049534 A1. USA Publication date, December 28, 2019. European Patent issued (Suisse, Allemagne, France, Grande Bretagne) September, 2020, US patent granted September 6, 2022, US 11,434,255 B2. Applicants (LCB Pharma, Université d’Ottawa), Inventors :  Guindon, Y., Mochirian, P., Nemer, M.
 
“Nucleoside analogues and methods of use thereof”, 2017, Application # PCT/CA2017/051096, International Publication date March 22, 2018, WO2018/049535 A1. USA publication date : October 24, 2019.  US patent granted September 27, 2022. Applicants : LCB Pharma Inc., Université d’Ottawa. Inventors: Guindon, Y., Mochirian, P., Nemer, M., Prévost, M.
 
"Nucleoside analogues with quaternary carbon stereogenic centers and methods of use”. Priority date March 18, 2008.  International Patent Application No PCT/IB2009/182009/005470 filed on March 18, 2008. US Patent 8846636. Date of patent September 30,2014. Application No 9 722 452.1. Canada Patent No 2,755,235.  Received on March 5, 2014. Patent no. 2,755,235, March 2014. European Patent issued: May 15, 2019; EP2265626B1; Assignee: LCB Pharma inc.; Inventor: Guindon, Y.
 
“Nucleotide and nucleoside analogues with quaternary carbon centers and methods of use”. International Patent Application No PCT/IB2208/000697 filed on January 17, 2008. US Patent No 8,361,988 B2 issued on January 29, 2013.  Assignee: Institut de recherches cliniques de Montréal. Inventor : Guindon Y.

“Nucleoside and Nucleotide Analogues Bearing a Quaternary All-carbon Stereocenter at the 2’ Position and Methods of Use as a Cardioprotective Agent”, 2017, Application # PCT/CA2017/051095; International Publication Date March 22, 2018, WO2018/049534 A1. USA Publication  date, December 28, 2019. European Patent issued (Suisse, Allemagne, France, Grande Bretagne) September 2020, Applicants (LCB Pharma, Université d’Ottawa), Inventors :  Guindon, Y., Mochirian, P., Nemer, M.

“Nucleoside analogues and methods of use thereof”, 2017, Application # PCT/CA2017/051096, International Publication date March 22, 2018, WO2018/049535 A1. USA publication date: October 24, 2019. Applicants : LCB Pharma Inc., Université d’Ottawa. Inventors : Guindon, Y., Mochirian, P., Nemer, M., Prévost, M. 

"Nucleoside analogues with quaternary carbon centers and methods of use”. Priority date March 18, 2008.  International Patent Application No PCT/IB2009/182009/005470 filed on March 18, 2008. US Patent 8846636. Date of patent September 30,2014. Application No 9 722 452.1. Canada Patent No 2,755,235.  Received on March 5, 2014. Patent no. 2,755,235, March 2014. Assignee : LCB Pharma inc. Inventor: Guindon, Y.

“Nucleotide and nucleoside analogues with quaternary carbon centers and methods of use”. International Patent Application No PCT/IB2208/000697 filed on January 17, 2008. US Patent No 8,361,988 B2 issued on January 29, 2013.  Asignee: Institut de recherches cliniques de Montréal. Inventor : Guindon Y.

"Process for the Preparation of Enantiomerically Pure (S,S) Aminoepoxides, Key Intermediates for HIV Protease Inhibitors, via their Chlorohydrines";
P. L.  Beaulieu, Y. Guindon and D. M.  Wernic;
European Patent 9,796,239 (March 31, 1999) 

"Synergistic Combination for Treating Herpes Infections";
R.  Déziel et Y. Guindon;
Brevet européen EP 0 493 767 B1 (19 mars 1997)    
Brevet canadien 2,033,447 (30 décembre 1990)

"Process for Key Intermediates for HIV Protease Inhibitors";
P. L.  Beaulieu, Y. Guindon et D. M.  Wernic;
Brevet canadien 2,033,448 (26 novembre 1996)
Brevet américain 5,550,291 (27 août 1996) 
Brevet européen 9,796,239 (31 mars 1999) 

"Antiherpes Compositions and Method of Use";  
R. Déziel, et Y. Guindon;
Brevet canadien 2,033,448 (26 novembre 1996)
Brevet américain 5,552,384 (3 septembre 1996)

"9-Benzyl-Tetrahydrocarbazole-1-Alkanoic Acids - Are Prostaglandin or 5-Lipoxygenase Antagonists Antithrombotic Agents etc."; 
J. W.  Gillard, Y. Guindon et C. Yoakim;
Brevet canadien 1,299,577 (28 avril 1992) 

"New 3-(1-benzyl-2-indolyl)-Alkanoic Acid Derivs. - are Leukotriene Inhibitors and Prostaglandin Antagonists, Used for Treating Asthma, Inflammation, Hypertension, Premature Labour, etc."; 
Y. Guindon, J. W.  Gillard, C.  Yoakim, T. R.  Jones et R.  Fortin;
Brevet américain 5,081,145 (14 janvier 1992) 

"New 5-hydroxy-2,3-dihydro-benzofuran Analogues - as Leukotriene Biosynthesis Inhibitors Against Inflammatory and Cardiovascular Disorders";
P. C. Bélanger, C. K. Lau, C. Dufresne, J. Rokach, Y. Guindon, J. Schiegetz, R. N. Young et M. Thérien;
Application de brevet européen 447189 (18 septembre 1991) 

"New cyclo-hept-(b)-indole-alkanoic Acids - Act as Prostaglandin and Thromboxane Antagonists and are Useful in Treating Asthma, Hypertension, Cerebral Spasm, etc.". 
J. W. Gillard, Y. Guindon, H. E. Morton, Y. Girard et C. Yoakim;
Brevet américain 5,017,593 (21 mai 1991) 

"Antiherpes Compositions and Method of Use";  
R. Déziel et Y. Guindon;
Application de brevet canadien 2,033,448 (1 juillet 1992)
Application de brevet américain 058,066 (4 mai 1993) 

"Enzyme Inhibitors";  
P. C. Anderson, Y. Guindon et C. Yoakim;
Brevet canadien 2,016,656 (14 mai 1990)
Brevet américain 5,212,157 (18 mai 1993) 

"Ribonucleotide Reductase Inhibitors";  
Y. Guindon, P. Lavallée, S. Rakhit et G. Cosentino;
Brevet américain 5,071,835 (10 décembre 1991)
Brevet canadien 1,327,869 (15 mars 1994) 

"HIV Protease Inhibiting Agents";  
P. C. Anderson, Y. Guindon, N. Moss, M. A. Poupart et C. Yoakim;
Application de brevet américain 869,412 (16 avril 1992)
Application de brevet canadien 2,036,398 (24 août 1991) 

"5-Lipoxygenase Activating Protein";
J. W. Gillard, J. F. Evans, J. Y. Gauthier, R. Fortin, Y. Guindon, D. K. Miller et R. A. F. Dixon;
Application de brevet américain déposée le 15 décembre 1989;
Brevet canadien 2,032,253 (16 juin 1991) 

"Compsn. for Inhibiting Leukotriene(s) - Contg. Benzo-Phenothiazine or -Phenoxazine Derivatives Useful for Treating e.g. Allergy, Asthma, Cardiovascular Disorders, Inflammation, etc."; 
Y. Guindon, Y. Girard, C. K. Lau, R. Fortin, J. Rokach et C. Yoakim;
Brevet américain 4,876,246 (24 octobre 1989) 

"New 2-s-Glutathionyl-3H-Phenothiazin-3-One Compounds - Used as Leukotriene Biosynthesis Inhibitors or Antagonists of Phenothiazinone"; 
C. K. Lau, C. Yoakim, J. Rokach, R. Fortin et Y. Guindon;
Brevet américain 4,859,667 (22 août 1989) 

"Enzyme Inhibiting Peptide Derivatives";   
P. C. Anderson, Y. Guindon et C. Yoakim;
Brevet américain 5,126,326 (30 juin 1992)
Application de brevet canadien 2,016,663 (14 mai 1990) 

"New Phenoxypropoxyphenylacetic Acid Derivatives Related Compounds - Useful as Leukotriene Antagonists in Treatment of Asthma, Allergic Rhinitis, Chronic Bronchitis, Psoriasis, Atopic Aczema, etc."; 
P. Bélanger, R. Fortin, Y. Guindon, C. Yoakim et J. Rokach;
Brevet américain 4,820,867 (11 avril 1989) 

"New Tetra-Hydro-Carbazole Alkanoic Ester(s) - Useful as Prostaglandin Antagonists, Leukotriene Inhibitors, Antithrombotic Agents and Cytoprotective Agents";   
J. W. Gillard, C. Yoakim, Y. Guindon et Y. Girard;    
Application de brevet européen 310179 (5 avril 1989)
Brevet américain 4,940,719 (10 juillet 1990) 

"New Cyclohept (b) Indole-Alkanoic Acids and Derivatives - Useful as Prostaglandin and Thromboxane Antagonists and Leukotriene Inhibitors";
J. W. Gillard, Y. Guindon, H. E. Morton, Y. Girard et C. Yoakim;    
Application de brevet européen 304156 (22 février 1989) 

"New 3-Alkyl-Benzofuran-4,7-Dione Derivatives - Useful as Leukotriene Biosynthesis Inhibitors for Treating e.g. Allergic Conditions and Asthma"; 
J. Adams, P. C. Bélanger, J. Rokach, Y. Guindon et M. L. Belley;
Application de brevet européen 301692 (1er février 1989) 

"New 9-Substituted Benzyl - Difluoro Tetrahydrocarbazolylacetic Acid - Useful as Leukotriene Synthesis Inhibitors and Prostaglandin Antagonists";
Y. Guindon, C. Yoakim, J. W. Gillard et Y. Girard;
Application de brevet européen 300676 (25 janvier 1989)
Brevet américain 4,808,608 (28 février 1989)
Brevet américain 5,021,447 (4 juin 1991) 

"New 4,7-Diacetoxy-2-Methoxybenzyl-3,5,6-Trimethyl-Benzofuran - Useful as Leukotriene Biosynthesis Inhibitors for Treating, e.g. Allergic Conditions and Inflammation"; 
J. Adams et Y. Guindon;
Brevet américain 4,800,228 (24 janvier 1989)
Brevet américain 4,912,131 (27 mars 1990) 

"New 3-Alkyl-4,7-Diacyloxy-Benzofuran Derivatives - Useful as Leukotriene Biosynthesis Inhibitors for Treating, e.g. Allergic Conditions"; 
J. Adams et Y. Guindon;
Application de brevet européen 295851 (21 décembre 1988) 

"Methods and Compositions for Combatting Herpes Infections";  
Y. Guindon;
Brevet canadien 1,324,086 (9 novembre 1993)
Brevet américain 5,314,914 (24 avril 1994)   

"Treating Herpes Viral Infections";  
Y. Guindon;
Brevet canadien 1,323,574 (26 octobre 1993)
Brevet américain 5,242,946 (7 septembre 1993) 

"New 4, 7-Benzofurandione Derivatives - are Inhibitors of Leukotriene Biosynthesis, Useful as Analgesics and for Treating, e.g. Asthma, Angina, Psoriasis, Eczema etc."; 
J. Adams, Y. Guindon, P. C. Bélanger, O. M. L. Belley et J. Rokach;
Brevet américain 4,778,805 (18 octobre 1988)
Brevet américain 4,968,821 (6 novembre 1990) 

"New Cyclohept (b) Indolealkanoic Acids - for Prostaglandin and Thromboxane Antagonists, e.g. for Treating Asthma, Hypertension, Angina, Spontaneous Abortion, etc.";
J. W. Gillard, Y. Guindon, H. E. Morton et Y. Girard;
Brevet américain 4,775,680 (4 octobre 1988)
Brevet américain 4,906,654 (6 mars 1990)
Brevet américain 5,017,597 (21 mai 1991)

"New 1-Optionally Substituted Benzyl-2,3-Disubstituted Indole Derivatives - Inhibitors of Leukotriene Synthesis, Useful, e.g. as Anti-Inflammatory Agents"; 
J. W. Gillard, H. E. Morton, R. Fortin et Y. Guindon;
Application de brevet européen 275667 (27 juillet 1988)
Brevet américain 5,081,138 (14 janvier 1992)

"New Phenoxypropyl and Phenoxybutenyl Phenyl (thio) Ether Compounds - are Leukotriene Antagonists and Inhibitors of Leukotriene Biosynthesis"; 
P. C. Bélanger, R. Fortin, Y. Guindon, J. Rokach et C. Yoakim;    
Application de brevet européen 252639 (13 janvier 1988)

"New 1-Alkoxycarbonyl-Alkyl-9-Benzyl-Tetrahydro-Carbazole Derivatives - Useful as Inhibitors of Leukotriene Synthesis and as Prostaglandin Antagonists"; 
Y. Guindon, J. W. Gillard et C. Yoakim;
Application de brevet européen 239306 (30 septembre 1987) 

"New 9-Benzyl-1-Substituted-Alkyl-1,2,3,4-Tetrahydro-Carbazole Derivatives - Useful as Inhibitors of Prostaglandin(s) and Thromboxane(s) esp. Anti-Asthmatics, Antiallergy and Antithrombotic Agents"; 
Y. Guindon, C. Yoakim et J. W. Gillard;
Application de brevet européen 234708 (2 septembre 1987) 

"Phenothiazone Derivatives and Analogues Useful as Leukotriene Inhibitors for Treating Allergies, Cardiovascular Disorders, Inflammation and Skin Diseases"; 
C. K. Lau, C. Yoakim, J. Rokach, R. Fortin et Y. Guindon;
Brevet américain 4,667,032 (19 mai 1987)
Brevet américain 4,939,145 (3 juillet 1990)

"Phenothiazine Derivatives and Analogues Useful as Leukotriene Biosynthesis Inhibitors for Treating Allergies, Cardiovascular Disorders, Inflammation, Skin Diseases etc."; 
R. Fortin, C. K. Lau, Y. Guindon, J. Rokach et C. Yoakim;
Brevet américain 4,666,907 (19 mai 1987)
Brevet américain 4,845,083 (4 juillet 1989)

"New 1,4-Diaza-Phenothiazines Compounds Used for Treating Allergic Conditions, Cardiovascular Disorders, Inflammation, Skin Conditions and Pain"; 
J. G. Atkinson, Y. Guindon, P. C. Bélanger et J. Rokach;
Brevet américain 4,634,766 (6 janvier 1987) 
Brevet américain 4,749,699 (7 juin 1988) 

"Benzofuran 2-Carboxylic Acid Esters Useful as Inhibitors of Leukotriene Biosynthesis";  
J. G. Atkinson, Y. Guindon et C. K. Lau;
Application de brevet européen 200443 (5 novembre 1986)
Brevet américain 4,663,347 (5 mai 1987)
Brevet américain 4,745,127 (17 mai 1988) 
Brevet américain 4,822,803 (18 avril 1989)
Brevet américain 4,933,351 (12 juin 1990)

"New Benzo(a)-Phenothiazine(s) and Hydro-Derivatives Useful as Inhibitors of Leukotriene Biosynthesis, and Treating, e.g. Allergies, Asthma, Cardiovascular Disorders, Inflammation and Pain"; 
Y. Guindon, Y. Girard, C. K. Lau, R. Fortin, J. Rokach et C. Yoakim;
Brevet américain 4,611,056 (9 septembre 1986)

"New 4-Oxo-Benzopyran Carboxylic Acids which Antagonize SRS-A and Leukotriene(s), Useful in Treatment of Allergic Conditions, Skin Diseases, Inflammation and Cardiovascular Disorders"; 
R. N. Young, J. Rokach, H. R. Williams, M. Kakushima et Y. Guindon;
Brevet américain 4,609,744 (2 septembre 1986)
Brevet américain 5,017,583 (21 mai 1991)

"4(R)-Hydroxy-Tetrahydro-2H-Pyranone-2-Derivatives Used as HMG-CoA Reductase Inhibitors";
Y. Guindon, H. E. Morton et C. Yoakim;
Application de brevet european 183132 (4 juin 1986)
Brevet américain 4,611,068 (9 septembre 1986)
Brevet canadien 1,245,226 (22 novembre 1988)
Brevet américain 4,855,481 (8 août 1989)
Brevet canadien 1,273,352 (28 août 1990)
Brevet canadien 1,288,352 (3 septembre 1991)

"New and Known 1-Benzyl-2-Carboxy-Alkyl-Indole Derivatives Useful as Prostaglandin Antagonists and Leukotriene Inhibitors for Treating Asthma, Cardiac Disorders etc.";
Y. Guindon, J. W. Gillard, C. Yoakim, T. R. Jones et R. Fortin;
Application de brevet européen 166591 (2 janvier 1986)
Brevet canadien 1,241,660 (6 septembre 1988)

"New 2-Substituted-Benzofuran and-Benzothiophene Derivatives Useful as Inhibitors of Mammalian 5-Lipoxygenase for Controlling Leukotriene Biosynthesis"; 
J. G. Atkinson, Y. Guindon et C. K. Lau;
Application de brevet européen 146243 (26 juin 1985)
Brevet canadien 1,281,329 (12 mars 1991)

"New 1,4-Diaza-Phenothiazine Derivatives are 5-Lipoxygenase Inhibitors Useful for Preventing Leukotriene Biosynthesis"; 
J. G. Atkinson, P. C. Bélanger, Y. Guindon et J. Rokach;
Application de brevet européen 140709 (8 mai 1985)
Brevet canadien 1,261,834 (26 septembre 1989) 

"New and Known Phenothiazine Derivatives and Analogues Useful as Leukotriene Biosynthesis Inhibitors";
R. Fortin, Y. Guindon, C. K. Lau, J. Rokach et C. Yoakim;
Application de brevet européen 138481 (24 avril 1985)
Brevet canadien 1,272,722 (14 août 1990) 

"New and Known Benzo-Phenothiazine Derivatives and Analogues Useful as Leukotriene Inhibitors for Treating Allergies, Pain etc."; 
R. Fortin, Y. Girard, Y. Guindon, C. K. Lau, J. Rokach et C. Yoakim;
Application de brevet européen 136893 (10 avril 1985)
Brevet canadien 1,272,721 (14 août 1990)

"New Alkanoic Acid Derivatives Useful as Leukotriene Antagonists for Treating Allergic and Cardiovascular Diseases"; 
R. N. Young, H. W. R. Williams, J. Rokach, M. Kaukushima et Y. Guindon;
Application de brevet européen 123543 (31 octobre 1984)

"New 2,4-Disubstituted-Phenoxy-Propoxy-Acetophenone Derivatives Useful as Antagonists of Leukotriene D4 for Treating Allergic Diseases etc."; 
P. Bélanger, Y. Guindon, R. Fortin, C. Yoakim et J. Rokach. ;
Application de brevet européen 123541 (31 octobre 1984)

"Pharmaceutical Composition for Inhibiting Leukotriene Biosynthesis Contains Phenothiazine Derivative or Analogue";
Y. Guindon, R. Fortin, C. K. Lau, J. Rokach et C. Yoakim;
Application de brevet européen 115394 (8 août 1984)
Brevet canadien 1,262,544 (31 octobre 1989)

"Composition Containing Phenothiazine Derivative or Analogue Useful as Inhibitors of Leukotriene Biosynthesis";
Y. Guindon, R. Fortin, C. K. Lau, J. Rokach et C. Yoakim;
Application de brevet australien 84-23269 (26 juillet 1984)

"2-Hydroxy-3-Alkyl-4-Substd.-Phenylthio-Alkoxy-Acetophenone(s) Useful as Leukotriene Antagonists for Anti-Allergy Use and Anti-Asthmatic Anti-Allergy Agents"; 
R. Fortin, Y. Guindon, J. Rokach et C. Yoakim;
Application de brevet européen 106565 (25 avril 1984)
Brevet canadien 1,273,349 (28 août 1990)

"2,6-Disubstituted-3-Phenoxy-Alkoxy-Phenol Derivatives and Analogues Useful as Leukotriene Antagonists and Inhibitors of their Synthesis";
P. Bélanger, B. Fortin, Y. Guindon, J. Rokach et C. Yoakim;
Application de brevet européen 104885 (4 avril 1984)
Brevet canadien 1,210,770 (2 septembre 1986) 

Important Discoveries

Tools

 
Press review
Press review
Grants
Recognitions and honors
  • Fellow, American Association for the Advancement of Science (AAAS) (2014)
  • Chevalier de l’Ordre National du Québec, 2012 (CQ)
  • Alfred-Bader Award, Canadian Society of Canada (2012)
  • President, Royal Society of Canada : The Academies of Arts, Humanities and Sciences of Canada (2007-2009)
  • Member of the Club des diplômés émérites, Université de Montréal (2006)
  • Laureate of the Prix Lionel-Boulet - Prix du Québec (2006)
  • Laureate of the  Prix Marcel-Piché, IRCM, (2005)
  • Member of the Order of Canada (CM) (2004)
  • Fellow, Royal Society of Canada : Academy of Sciences (FRSC) (1990)
  • Fellow, Chemical Institute of Canada (FCIC) (1988) 

Join the
group Research

Available positions

Ongoing clinical studies

Research Partners

Join the
research group

514 987-5786
yvan.guindon@ircm.qc.ca

Life in the
laboratory

Newsletter

Discoveries,
events and more

Subscribe

IRCM Foundation

Be part of the
solution

Support health research

110, ave des Pins West,
Montréal (Québec) Canada
H2W 1R7
514 987-5500

Partners 

 

Research
Platforms
Student life
Admissions
The Institure
Events
The Clinic
Careers
Contact us
News
Newsroom

© Montreal Clinical Research Institute, Année.All rights reserves. | Privacy policy | Terms of use | Web site by Agence Riposte

Support the Foundation
Powered by Yapla Logo